tbuckley/cabot-search huggingface dataset:
Maternal Disability and Emergency Department Use for Infants
Authors: Hilary K. Brown, Yona Lunsky, Kinwah Fung, Maria Santiago-Jimenez, Andi Camden, Eyal Cohen, Joel G. Ray, Natasha R. Saunders, Deanna Telner, Catherine E. Varner, Simone N. Vigod, Jennifer Zwicker, Astrid Guttmann
Journal: JAMA Network Open (2025)

Importance Infants have among the highest rates of emergency department (ED) visits of all age groups. Women with disabilities experience significant social disparities, may experience barriers accessing child primary care, and may seek care in the ED. Objective To compare ED use among newborns and infants (hereafter infants) of women with or without disabilities, overall and by timing and acuity of the ED visit. Design, Setting, and Participants This population-based cohort study analyzed data for all live-born infants in Ontario, Canada, born to women with or without a disability from April 1, 2008, to March 31, 2021. Data were analyzed March 2023 to October 2024. Exposure Maternal physical, sensory, or intellectual or developmental disability or multiple disabilities status was ascertained using diagnostic algorithms applied to health care encounters before delivery. Main Outcomes and Measures The main outcome was any ED visit between an infant’s hospitalization discharge date and their first birthday, and by timing and acuity. Cox proportional hazards regression was used to generate hazard ratios (HRs) for the association between maternal disability and the main outcome, adjusted for sociodemographic characteristics and infant sex and year of birth. Results Of 1 596 932 total infants, there were 139 698 (8.7%) born to women with a physical disability, 48 112 (3.0%) to women with a sensory disability, 2547 (0.2%) to women with an intellectual or developmental disability, and 10 312 (0.6%) to women with multiple disabilities. The remaining 1 396 263 infants (87.4%) were born to a woman without a recognized disability. Among women without a disability, 558 965 infants (40.0%) had an ED visit in the first year of life (incidence rate, 1.11 per 1000 person-days). Compared with this referent group, infants born to a woman with a disability of a physical (46.9%; 1.30 visits per 1000 person-days; adjusted HR [AHR], 1.14 [95% CI, 1.13-1.15]), sensory (45.2%; 1.25 visits per 1000 person-days; AHR, 1.09 [95% CI, 1.07-1.10]), or intellectual or developmental (55.4%; 1.55 visits per 1000 person-days; AHR, 1.24 [95% CI, 1.17-1.30]) nature or with multiple disabilities (51.0%; 1.42 visits per 1000 person-days; AHR, 1.18 [95% CI, 1.15-1.22]) were more likely to have an ED visit. Similar patterns were observed for ED visits at fewer than 28 days from delivery, from 28 to 365 days, and for ED visits for high-acuity, moderate-acuity, and low-acuity reasons. Conclusions and Relevance In this population-based cohort study, infants of women with disabilities were more likely to use the ED, indicating a need for accessible family supports and improved early child primary care access.
Medicaid Costs and Outcomes for Patients Treated in an Outpatient Telepsychiatry Clinic
Authors: John L. Havlik, Reza H. Ghomi, Na An, Puneet Budhiraja, Eric R. Arzubi
Journal: JAMA Network Open (2025)

Importance Evidence of cost savings attributable to indicated and timely care remain rare in psychiatry. Interventions to provide evidence-based psychiatric care to Medicaid patients that lower total costs of care are particularly challenging. Objective To investigate Medicaid costs and care outcomes associated with use of an outpatient telepsychiatry clinic. Design, Setting, and Participants This cross-sectional study analyzed Medicaid patients using and not using the services of an outpatient telepsychiatry clinic (Frontier Psychiatry, Billings, Montana) in 2022. Data analysis was performed from June to September 2024. Exposure Receipt of care through an outpatient telepsychiatry clinic. Main Outcomes and Measures Differences in Medicaid costs and cost subtypes between telepsychiatry patients and controls were assessed. Quality metrics, including inpatient hospitalizations, hospital readmissions, and admissions from the emergency department, were also compared. Results In total, there were 2686 patients using the outpatient telepsychiatry clinic’s services (1665 female [62.0%]; mean [SD] age, 30.55 [14.67] years) and 2686 propensity–matched controls (1665 female [62.0%]; mean [SD] age, 31.37 [15.92] years). Across categories examined, the telepsychiatry patients had care costs per member per month (PMPM) similar to those for propensity-matched control patients ($685.5 [95% CI, $632.9-$738.2] vs $734.0 [95% CI, $645.7-$822.3]; P = .10) over the study period. PMPM costs to Medicaid from the telepsychiatry clinic’s patients were higher for professional services vs control patients ($464.0 [95% CI, $443.4-$484.5] vs $388.4 [95% CI, $368.1-$408.7]; P &amp;amp;lt; .001) but were lower for inpatient hospitalization fees ($201.6 [95% CI, $146.2-$228.7] vs $260.6 [95% CI, $220.2-$341.5]; P = .04). Telepsychiatry clinic patients had a 38.0% lower mean annualized hospitalization rate per 1000 patients than controls (274.3 [95% CI, 237.1-311.6] hospitalizations per 1000 patients vs 442.6 [95% CI, 396.5-488.7] hospitalizations per 1000 patients; P &amp;amp;lt; .001) and a 17.9% lower rate of admissions from the emergency department (patients vs controls, 299.7 admissions [47.7%] vs 519.0 admissions [58.1%]). Conclusions and Relevance In this cross-sectional study of 5372 patients, use of an outpatient telepsychiatry clinic’s services was associated with decreases in inpatient hospitalization rates and lower rates of admissions from the emergency department, with similar costs to Medicaid. These findings suggest that outpatient telepsychiatry care could play an important role in reducing hospital admissions among patients enrolled in Medicaid.
Landscape assessment of patient-reported outcome item coverage of tyrosine kinase inhibitor-associated AEs
Authors: Emily L Paton, Jeremy P Cetnar, Janet Freeman-Daily, Jill Feldman, Bellinda L King-Kallimanis
Journal: JNCI Journal of the National Cancer Institute (2025)

Abstract Background Patient-reported outcomes (PROs) are critical for assessing symptomatic adverse events (AEs) in non-small-cell lung cancer (NSCLC) clinical trials. However, PROs may not fully capture tyrosine kinase inhibitor (TKI)-specific AEs in metastatic NSCLC patients. This study evaluated coverage of TKI-related symptomatic AEs by commonly used PRO item libraries. Methods We compiled a list of FDA-approved TKIs for NSCLC with alterations in EGFR, ALK, ROS1, RET, MET, and NTRK. Symptomatic AEs were extracted from clinical trials reported in US Prescribing Information (ie,, drug labels). The European Organisation for Research and Treatment of Cancer (EORTC), Patient-Reported Outcomes Measurement Information System (PROMIS), and Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) item libraries were searched for items corresponding to extracted AEs. Items were classified according to the AE’s physical, functional, or social/emotional impact. Results Data from 17 drug labels covering 29 clinical trials of 17 TKIs were analyzed. By TKI, EORTC covered the highest average percentage of AEs (99%), followed by PRO-CTCAE (86%), and PROMIS (47%). Of the 15 most common AEs, 8 were covered by all 3 item libraries. EORTC and PRO-CTCAE covered 15 AEs, whereas PROMIS covered 8. Of the 8 AEs covered by all 3 libraries, PROMIS included the most items assessing functional and social/emotional impact. Conclusions EORTC and PRO-CTCAE covered more symptomatic AEs than PROMIS. For the AEs it covered, PROMIS had the most items assessing functional and social/emotional impact. Our assessment is a starting point for improving PRO coverage of AEs associated with new treatments like TKIs.
Genome-wide Meta-Analysis of Heavy Menstrual Bleeding Reveals 36 Risk Loci
Authors: Florian Thibord, Jason Cunha, Jelisaveta Dzigurski, Bjoernar Tuftin, Jennifer E. Huffman, Natàlia Pujol-Gualdo, Kelly Cho, Peter WF Wilson, Jill M. Johnsen, Laura M Raffield, Ming-Huei Chen, Triin Laisk, Andrew D Johnson
Journal: Blood (2025)
Sodium-Glucose Cotransporter 2 Inhibitors in Tafamidis-Treated Transthyretin Amyloid Cardiomyopathy
Authors: Kuan-Yu Chi, Dimitrios Varrias, Pawel Borkowski, Anita Osabutey, Junmin Song, Cho-Han Chiang, Yu-Cheng Chang, Pei-Lun Lee, Yu Chang, Robert T Faillace, Ulrich Jorde, Omar Saeed, Jose Gonzalez-Costello, Shivank Madan, Snehal R Patel
Journal: JACC Heart Failure (2025)
Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD
Authors: Katharina Marie Habenicht, Jana Wanzek, Anna Bootz, Simon Schäfer, Lara Vollmer, Andreas Hiergeist, Matthias Alexander Fante, Jakob Thomas Hasenbank, Andrea Schneider, Ingrid Vasova, Silvia Spoerl, Anna Brandt, Michael Rehli, Petra Hoffmann, Stefan Wirtz, Jesika Kotorri, Roman G Gerlach, André Gessner, Andreas Mackensen, Julia Winkler, Daniel Wolff, Thomas H Winkler
Journal: Blood (2025)
Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients
Authors: Paul Gautier, Meyer Elbaz, Julien Bezin, Clément Delmas, Miloud Cherbi, Frédéric Bouisset, Cécile Vindis, Axel Renoux, Margaux Lafaurie, François Montastruc
Journal: JACC Heart Failure (2025)
Days Alive Out of Hospital for Patients with Left Ventricular Dysfunction
Authors: Kamil F Faridi, Haocheng Huang, Helen Parise, Tariq Ahmad, Makoto Mori, Mabel Chung, Robert W Yeh, Mark C Petrie, Julio A Panza, Jean L Rouleau, Rafal Dabrowski, Eric J Velazquez
Journal: JACC Heart Failure (2025)
Effect of Uptitration of Recommended Heart Failure Medications on Restricted Mean Survival Time in STRONG-HF
Authors: Ashok Krishnaswami, Beth A Davison, Christopher Edwards, Gad Cotter, Marco Metra, Ovidiu Chioncel, Karen Sliwa, Adriaan A Voors, Alexandre Mebazaa, Deepak L Bhatt
Journal: JACC Heart Failure (2025)
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial
Authors: David D Berg, Siddharth M Patel, Paul M Haller, Jan Bělohlávek, Akshay S Desai, Jarosław Drożdż, Silvio E Inzucchi, John J V McMurray, Béla Merkely, Eileen O'Meara, Subodh Verma, Abby L Cange, Sabina A Murphy, Marc S Sabatine, Stephen D Wiviott
Journal: JACC Heart Failure (2025)
In early postmenopausal women, zoledronate vs. placebo at baseline and 5 y reduced morphometric vertebral fractures at 10 y
Authors: Yu Qing Huang, Jennifer Watt
Journal: Annals of Internal Medicine (2025)

GIM/FP/GP: [Formula: see text] Endocrinology: [Formula: see text] Geriatrics: [Formula: see text] Public Health: [Formula: see text].
Guideline recommends antiviral prophylaxis for patients at high risk for HBV reactivation
Authors: Sana A. Pirzada, Averell H. Sherker
Journal: Annals of Internal Medicine (2025)

GIM/FP/GP: [Formula: see text] Gastroenterology: [Formula: see text] Infectious Disease: [Formula: see text] Public Health: [Formula: see text].
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study
Authors: Santiago Escrivá-de-Romani, Juan M Cejalvo, Emilio Alba, Jennifer Friedmann, Álvaro Rodríguez-Lescure, Marie-France Savard, Rossanna C Pezo, Maria Gion, Manuel Ruiz-Borrego, Erika Hamilton, Timothy Pluard, Marc Webster, Muralidhar Beeram, Hannah Linden, Cristina Saura, Diana Shpektor, Bob Salim, Phoebe Harvey, Sara A Hurvitz
Journal: The Lancet Oncology (2025)
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop
Authors: Antoine Kimmoun, Connor O'Brien, Vanessa Blumer, Florian A Wenzl, Janine Pöss, Uwe Zeymer, Jacob E Møller, Nadia Aissaoui, Shashank S Sinha, Alain Combes, Naoki Sato, Alessandro Sionis, Sabri Soussi, Susanna Price, Rhonda E Monroe, Rebecca Mathew, Alexandre Mebazaa
Journal: The Lancet Respiratory Medicine (2025)
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case–control study
Authors: Gonzalo Pérez Marc, Carla Vizzotti, Deshayne B Fell, Lucila Di Nunzio, Santiago Olszevicki, Shauna Wolf Mankiewicz, Virginia Braem, Ramiro Rearte, Jessica E Atwell, Alejandra Bianchi, Nora Fuentes, Romina Zadoff, Gabriela Vecchio, María Gabriela Abalos, Rong Fan, Graciela Del Carmen Morales, Bradford D Gessner, Luis Jodar, Romina Libster, Analía Rearte
Journal: The Lancet Infectious Diseases (2025)
Echocardiographic Nomograms in Children Living at High Altitude According to Sex
Authors: Demeke Mekonnen, Claire B Ren, Jorge Mercado, Victoria Garcia-Ruiz, Reto Kurmann, Fabian Zürcher, Peter Krähenmann, Nassip Llerena, Pedro Torres, Thomas Pilgrim, Ernest Spitzer
Journal:  (2025)

Abstract Aims This study aimed to establish 2D and M-mode echocardiographic reference values for cardiac chambers, outflow tracts, and great vessels for school children living at high altitudes, differentiated between males and females. Methods and results This post hoc analysis included children with normal echocardiography from a cluster randomized cross-sectional survey of rheumatic heart disease among school children in Peru. The echocardiograms were acquired with a portable machine and the images were analysed centrally with a standardized methodology. Body surface area (BSA) was used as an independent variable to predict the mean values of echocardiographic measurements for both male and female groups. Reference values are presented on z-scores and nomograms based on sex. Propensity score matching was used to compare sexes. A total of 985 students aged 5–16 years were included. The Haycock formula provided the best fit and was used when presenting data as predicted values for a given BSA. The z-score and nomograms for all essential parameters of cardiac chambers, great vessels, and functional surrogates are presented based on sex. The majority of the parameters were significantly different per sex after propensity score matching. Conclusion Normal reference values and nomograms of cardiac chambers, outflow tracts, and great arteries in healthy school children living at high altitudes based on sex were reported. These data partly addressed the existing gaps in paediatric echocardiographic nomograms.
Modeling the extension of ovarian function after therapeutic targeting of the primordial follicle reserve
Authors: Joshua Johnson, John W Emerson, Annika Smith, Kayla Medina, Evelyn E Telfer, Richard A Anderson, Sean D Lawley
Journal: Human Reproduction Update (2025)

Abstract BACKGROUND Women are increasingly choosing to delay childbirth, and those with low ovarian reserves indicative of primary ovarian insufficiency are at risk for sub- and infertility and also the early onset of menopause. Experimental strategies that promise to extend the duration of ovarian function in women are currently being developed. One strategy is to slow the rate of loss of existing primordial follicles (PFs), and a second is to increase, or ‘boost’, the number of autologous PFs in the human ovary. In both cases, the duration of ovarian function would be expected to be lengthened, and menopause would be delayed. This might be accompanied by an extended production of mature oocytes of sufficient quality to extend the fertile lifespan. OBJECTIVE AND RATIONALE In this work, we consider how slowing physiological ovarian aging might improve the health and well-being of patients, and summarize the current state-of-the-art of approaches being developed. We then use mathematical modeling to determine how interventions are likely to influence the duration of ovarian function quantitatively. Finally, we consider efficacy benchmarks that should be achieved so that individuals will benefit, and propose criteria that could be used to monitor ongoing efficacy in different patients as these strategies are being validated. SEARCH METHODS Current methods to estimate the size of the ovarian reserve and its relationship to the timing of the menopausal transition and menopause were compiled, and publications establishing methods designed to slow loss of the ovarian reserve or to deliver additional ovarian PFs to patients were identified. OUTCOMES We review our current understanding of the consequences of reproductive aging in women, and compare different approaches that may extend ovarian function in women at risk for POI. We also provide modeling of primordial reserve decay in the presence of therapies that slow PF loss or boost PF numbers. An interactive online tool is provided that estimates how different interventions would impact the duration of ovarian function across the natural population. Modeling output shows that treatments that slow PF loss would need to be applied as early as possible and for many years to achieve significant delay of menopause. In contrast, treatments that add additional PFs should occur as late as possible relative to the onset of menopause. Combined approaches slowing ovarian reserve loss while also boosting numbers of (new) PFs would likely offer some additional benefits in delaying menopause. WIDER IMPLICATIONS Extending ovarian function, and perhaps the fertile lifespan, is on the horizon for at least some patients. Modeling ovarian aging with and without such interventions complements and helps guide the clinical approaches that will achieve this goal. REGISTRATION NUMBER Not applicable.
Obesity and Autoimmunity Epidemic: The Role of Immunometabolism
Authors: Alessandra Colamatteo, Clorinda Fusco, Alessandro Matarese, Giuseppe Matarese
Journal: Annual Review of Nutrition (2025)

The relationship between obesity and autoimmune diseases has attracted significant attention in recent years, highlighting the multifaceted connection between metabolic dysregulation and loss of self-immune tolerance. Compelling epidemiological evidence has revealed an elevated prevalence of autoimmune diseases among overweight or obese individuals, suggesting a potential causal link. Mechanistically, adipose tissue is a key immunometabolic organ that secretes an array of adipocytokines that can facilitate proinflammatory immune responses against self - antigens. Indeed, adipose tissue dysfunction in obesity fosters a state of chronic low-grade inflammation, which may contribute to the so-called accelerator hypothesis, in which circulating self-autoreactive T cells can easily lose their regulatory mechanisms, resulting in self-tissue damage and autoinflammation. In this review, we elucidate the intricate immunometabolic pathomechanisms underlying the obesity and autoimmunity epidemic, and we explore innovative therapeutic avenues that could be pivotal for advancing public health initiatives in the context of this epidemic.
Current Clinical Applications of AAV-mediated Gene Therapy
Authors: Barry J Byrne, Kevin M Flanigan, Susan E Matesanz, Richard S Finkel, Megan A Waldrop, Eleonora S D'Ambrosio, Nicholas E Johnson, Barbara K Smith, Carsten Bönnemann, Sean Carrig, Joseph W Rossano, Barry Greenberg, Laura Lalaguna, Enrique Lara-Pezzi, Sub Subramony, Manuela Corti, Claudia Mercado-Rodriguez, Carmen Leon-Astudillo, Rebecca Ahrens-Nicklas, Diana Bharucha-Goebel, Guangping Gao, Dominic J Gessler, Wuh-Liang Hwu, Yin-Hsiu Chien, Ni-Chung Lee, Sanford L Boye, Shannon E Boye, Lindsey A George
Journal: Molecular Therapy (2025)
Discovery of Yersinia LcrV as a novel biased agonist of formyl peptide receptor 1 to bi-directionally modulate intracellular kinases in triple-negative breast cancer
Authors: Yunjun Ge, Huiwen Guan, Ting Li, Jie Wang, Liang Ying, Shuhui Guo, Jinjian Lu, Richard D. Ye, Guosheng Wu
Journal: Acta Pharmaceutica Sinica B (2025)
Discovery and proof-of-concept study of a novel highly selective sigma-1 receptor agonist for antipsychotic drug development
Authors: Wanyu Tang, Zhixue Ma, Bang Li, Zhexiang Yu, Xiaobao Zhao, Huicui Yang, Jian Hu, Sheng Tian, Linghan Gu, Jiaojiao Chen, Xing Zou, Qi Wang, Fan Chen, Guangying Li, Chaonan Zheng, Shuliu Gao, Wenjing Liu, Yue Li, Wenhua Zheng, Mingmei Wang, Na Ye, Xuechu Zhen
Journal: Acta Pharmaceutica Sinica B (2025)
International Union of Basic and Clinical Pharmacology. CXX. GHB protein targets in the mammalian brain - beyond classic receptors
Authors: Petrine Wellendorph, Stine Juul Gauger, Jens Velde Andersen, Birgitte Rahbek Kornum, Sara M.O. Solbak, Bente Frølund
Journal: Pharmacological Reviews (2025)
Homologous magnetic targeted immune vesicles for amplifying immunotherapy via ferroptosis activation augmented photodynamic therapy against glioblastoma
Authors: Hanwen Zhang, Kuanhan Feng, Mingzhi Han, Yali Shi, Yingjie Zhang, Jie Wu, Wanyi Yang, Xinrui Wang, Liuqing Di, Ruoning Wang
Journal: Journal of Controlled Release (2025)
High inherited risk predicts age-associated increases in fibrosis in patients with MASLD
Authors: Luis Antonio Díaz, William Alazawi, Saaket Agrawal, Juan Pablo Arab, Marco Arrese, Francisco Idalsoaga, Fernando Javier Barreyro, Adrian Gadano, Sebastián Marciano, Jorge Martínez Morales, Cristiane Villela-Nogueira, Nathalie Leite, Claudia Alves Couto, Rafael Theodoro, Mísia Joyner de Sousa Dias Monteiro, Claudia P Oliveira, Mario G Pessoa, Mario Reis Alvares-da-Silva, Egbert Madamba, Ricki Bettencourt, Lisa M Richards, Amit R Majithia, Amit V Khera, Rohit Loomba, Veeral Ajmera
Journal: Journal of Hepatology (2025)
Clinical stage of retinoblastoma based on presenting signs of 4,578 patients from 121 countries
Authors: Ryan T Yanagihara, Jamie S K Takayesu, Erin E Crotty, Xunda Ji, Yihua Zou, Sadia Sultana, Riffat Rashid, Sadik Taju Sherief, Nathalie Cassoux, Juan L Garcia Leon, Rosdali Y Diaz Coronado, Arturo Manuel Zapata López, Tatiana L Ushakova, Vladimir G Polyakov, Soma Rani Roy, Alia Ahmad, M Ashwin Reddy, Mandeep S Sagoo, Lamis Al Harby, Jesse L Berry, Ashley Polski, Nicholas J Astbury, Covadonga Bascaran, Sharon Blum, Richard Bowman, Matthew J Burton, Allen Foster, Nir Gomel, Naama Keren-Froim, Shiran Madgar, Marcia Zondervan, Swathi Kaliki, Ido Didi Fabian, Andrew W Stacey
Journal: Ophthalmology (2025)
Enhancing biomarker based oncology trial matching using large language models
Authors: Nour Alkhoury, Maqsood Shaik, Ricardo Wurmus, Altuna Akalin
Journal: npj Digital Medicine (2025)

Abstract Clinical trials are an essential component of drug development for new cancer treatments, yet the information required to determine a patient’s eligibility for enrollment is scattered in large amounts of unstructured text. Genomic biomarkers are especially important in precision medicine and targeted therapies, making them essential for matching patients to appropriate trials. Large language models (LLMs) offer a promising solution for extracting this information from clinical trial study descriptions (e.g., brief summary, eligibility criteria), aiding in identifying suitable patient matches in downstream applications. In this study, we explore various strategies for extracting genetic biomarkers from oncology trials. Therefore, our focus is on structuring unstructured clinical trial data, not processing individual patient records. Our results show that open-source language models, when applied out-of-the-box, effectively capture complex logical expressions and structure genomic biomarkers, outperforming closed-source models such as GPT-4. Furthermore, fine-tuning these open-source models with additional data significantly enhances their performance.
Locking CBL TKBD in its native conformation presents a novel therapeutic opportunity in mutant CBL-dependent leukemia
Authors: Syed Feroj Ahmed, Jayanthi Anand, Wei Zhang, Lori Buetow, Loveena Rishi, Louise Mitchell, Jonathan Bohlen, Sergio Lilla, Gary J Sibbet, Colin Nixon, Amrita Patel, Karolina A Majorek, Sara Zanivan, Jacinta C Bustamante, Sachdev S Sidhu, Karen Blyth, Danny T Huang
Journal: Molecular Therapy (2025)